HAWTHORNE, N.Y., Dec 31, 2007 (BUSINESS WIRE) -- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron
Cohen, M.D., President & CEO, will present at the upcoming JPMorgan
26th Annual Healthcare Conference on Monday, January 7, 2008 at 10:30
a.m. Pacific Standard Time (PST).
The conference is taking place at the Westin St. Francis Hotel,
335 Powell Street, San Francisco, CA. The presentation will be
available via a live webcast at http://www.metameetings.com/webcasts/jpmorgan/healthcare08.
Archived versions of the webcast will be available for 90 days.
Forward Looking Statements
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. All
statements, other than statements of historical facts, regarding
management's expectations, beliefs, goals, plans or prospects should
be considered forward-looking. These statements are subject to risks
and uncertainties that could cause actual results to differ
materially, including Acorda Therapeutics' ability to successfully
market and sell Zanaflex Capsules(R) (tizanidine hydrochloride), the
risk of unfavorable results from future studies of Fampridine-SR,
delays in obtaining or failure to obtain FDA approval of
Fampridine-SR, competition, the ability to obtain additional financing
to support Acorda Therapeutics' operations, unfavorable results from
its preclinical programs, and failure to protect its intellectual
property or to defend against the intellectual property claims of
others. These and other risks are described in greater detail in
Acorda Therapeutics' filings with the Securities and Exchange
Commission. Acorda Therapeutics may not actually achieve the goals or
plans described in its forward-looking statements, and investors
should not place undue reliance on these statements. Acorda
Therapeutics disclaims any intent or obligation to update any
forward-looking statements as a result of developments occurring after
the date of this press release.
About Acorda Therapeutics
Acorda Therapeutics is a biotechnology company developing
therapies for SCI, MS and related nervous system disorders. The
Company's marketed products include Zanaflex Capsules, a short-acting
drug for the management of spasticity. Acorda is conducting a Phase 3
clinical trial of Fampridine-SR to evaluate its safety and efficacy in
improving walking ability in people with MS. The Company's pipeline
includes a number of products in development for the treatment,
regeneration and repair of the spinal cord and brain.
SOURCE: Acorda Therapeutics, Inc.
Acorda Therapeutics
Tierney Saccavino, 914-347-4300 ext. 104
tsaccavino@acorda.com